Your missing links are here (4 December 2020)

Some of the best stuff we picked up around the internet

By: Karen O'Hanlon Cohrt - Dec. 4, 2020

Top picks



Clinical Trials


Meetings and Webinars

  • Warm up to the 62nd American Society of Hematology (ASH) annual meeting that is taking place virtually this weekend (December 5-8, 2020). Clinical data from several leaders in the CRISPR gene-editing field will be presented, including Cellectis, CRISPR Therapeutics and Penn University.
  • California-based Allogene Therapeutics announces webinar to review initial ALLO-715 Phase 1 data on December 5, 2020. The company is developing allogeneic CAR T (AlloCAR T™) therapies for cancer and the webinar will specifically include a discussion of results presented at the American Society of Hematology Annual Meeting from the ALLO-715 UNIVERSAL Phase 1 trial in relapsed/refractory multiple myeloma.

Heh, huh wow

  • Researchers at Norwegian University of Science and Technology is studying the effects of exercise at the cellular level and sees potential for gene therapies that may mimic the positive cellular effects for those that either cannot exercise or don’t respond well to physical exercise, so-called low-responders. The researchers were recently interviewed here and you can read more about their work in an earlier review article.


HashtagArticleHashtagMissing linksHashtagNews

CMN Webinars - Upcoming

CMN Webinars - Upcoming
CMN Webinars - Upcoming
News: Your missing links are here (4 December 2020)
Search CRISPR Medicine